Pharmacokinetics of dipeptidylpeptidase-4 inhibitors - Scheen, A.J (Diabetes, obesity & metabolism, 2010)
Keywords: Adamantane; Adamantane - analogs & derivatives; Adamantane - pharmacokinetics; Adamantane - therapeutic use; alogliptin; analogs & derivatives; Bioavailability; Clinical trials; Cytochrome P450; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 2 - drug therapy; Dipeptides; Dipeptides - pharmacokinetics; Dipeptides - therapeutic use; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; DPP-4 inhibitor; Drug dosages; Drug interaction; Drug Interactions; drug therapy; Enhancers; Female; Food intake; Glomerular filtration rate; Glucose; Half-Life; Human health sciences; Humans; Hypoglycemia; Hypoglycemic Agents; Hypoglycemic Agents - pharmacokinetics; Hypoglycemic Agents - therapeutic use; Insulin; Insulin secretion; Kidneys; linagliptin; Liver; Male; Metabolism; Metabolites; Metformin; Nitriles; Nitriles - pharmacokinetics; Nitriles - therapeutic use; Oral administration; Pharmacie, pharmacologie & toxicologie; Pharmacodynamics; Pharmacokinetics; Pharmacy, pharmacology & toxicology; Pyrazines; Pyrazines - pharmacokinetics; Pyrazines - therapeutic use; Pyrrolidines; Pyrrolidines - pharmacokinetics; Pyrrolidines - therapeutic use; Randomized Controlled Trials as Topic; Renal function; Renal insufficiency; saxagliptin; Sciences de la santé humaine; Secretion; sitagliptin; Sitagliptin Phosphate; therapeutic use; Triazoles; Triazoles - pharmacokinetics; Triazoles - therapeutic use; type 2 diabetes mellitus; vildagliptin